IFP Advisors’s Sinovac Biotech, Ltd SVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$0 Hold
200
﹤0.01% 5330
2026
Q1
$0 Hold
200
﹤0.01% 5209
2025
Q4
$0 Hold
200
﹤0.01% 5080
2025
Q3
$0 Hold
200
﹤0.01% 4986
2025
Q2
$0 Buy
+200
New ﹤0.01% 5080
2023
Q1
Sell
-18
Closed -$8K 4703
2022
Q4
$8K Hold
18
﹤0.01% 3575
2022
Q3
$8K Hold
18
﹤0.01% 3827
2022
Q2
$8K Hold
18
﹤0.01% 3573
2022
Q1
$8K Buy
+18
New +$8K ﹤0.01% 3572
2019
Q1
Sell
-1,000
Closed -$7K 4017
2018
Q4
$7K Hold
1,000
﹤0.01% 2734
2018
Q3
$8K Hold
1,000
﹤0.01% 3031
2018
Q2
$7K Sell
1,000
-1,000
-50% -$7.87K ﹤0.01% 3136
2018
Q1
$16K Hold
2,000
﹤0.01% 2549
2017
Q4
$16K Hold
2,000
﹤0.01% 2585
2017
Q3
$14K Hold
2,000
﹤0.01% 2861
2017
Q2
$14K Buy
2,000
+1,000
+100% +$5.48K ﹤0.01% 2835
2017
Q1
$6K Hold
1,000
﹤0.01% 3256
2016
Q4
$6K Hold
1,000
﹤0.01% 3257
2016
Q3
$6K Hold
1,000
﹤0.01% 3196
2016
Q2
$6K Buy
+1,000
New +$6.13K ﹤0.01% 3113
2016
Q1
Sell
-1,000
Closed -$6K 4559
2015
Q4
$6K Buy
+1,000
New +$5.38K ﹤0.01% 2930

Other funds holding SVA

IFP Advisors's SVA Position: Q2 2026 in Review

IFP Advisors held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 200 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5330.

IFP Advisors first reported a position in SVA in Q4 2015 and has held it in 21 quarters since. The position peaked at $16K in Q1 2018. 2 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

  • IFP Advisors held 200 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
  • IFP Advisors left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
  • Sinovac Biotech, Ltd made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5330 holding.
  • IFP Advisors first reported a position in Sinovac Biotech, Ltd in Q4 2015 and has held it in 21 quarters since.
  • IFP Advisors's Sinovac Biotech, Ltd position peaked at $16K in Q1 2018.
  • 2 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.